18-JUN-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     4029 376 181 86 27 4 02/06/2019 471 184
Screened at PD     1508 235 123 60 16 3      
Pre-Screened prior to PD     2497 123 48 22 8 1      
Treatment-naive     24 18 10 4 3 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     533 28 13 4 1 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2204 300 158 83 27 5      
Screened at PD     1281 234 129 70 23 5      
Pre-Screened prior to PD     842 46 18 8 1 0      
Treatment-naive     24 18 10 4 3 0      
After PD on a Lung_MAP Sub-Study     57 2 1 1 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     395 259 134 71 20 3      
S1900G     38 8 5 4 2 1      
S1900J     19 7 4 2 1 1      
S1900K     42 26 15 6 4 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     639 132 76 42 16 3      
Initial sub-study registrations     627 132 76 42 16 3      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 106 104 60 35 12 2 05/22/2025 349 115
Docetaxel plus Ramucirumab Y   55 54 30 19 6 1      
Cemiplimab plus Docetaxel and Ramucirumab Y   51 50 30 16 6 1      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   44 27 7 4 3 1 1 05/05/2023 338 107
Capmatinib + Osimertinib + Ramucirumab Y   15 5 2 1 1 1      
Capmatinib + Osimertinib Y   12 2 2 2 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 4 2 1 0 0 0 11/19/2024 283 84
Amivantamab Hyaluronidase Y   4 2 1 0 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 28 19 11 4 3 0 08/08/2024 270 89
Tepotinib + Ramucirumab Y   19 12 9 3 3 0      
Tepotinib Y   9 7 2 1 0 0